Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 491 (LINC00491) is a cytoplasmic long non-coding RNA transcribed from chromosome 5q21.1[1][6]. It is characterized as a competing endogenous RNA (ceRNA) that interacts with and "sponges" specific microRNAs, such as miR-145 in colon adenocarcinoma and miR-324-5p in non-small cell lung cancer, leading to increased expression of oncogenic proteins such as SERPINE1 and SP1[2][4][6]. LINC00491 is significantly upregulated in various cancers and promotes proliferation, migration, and invasion of cancer cells, while its knockdown increases apoptosis and reduces malignant phenotypes[3][5][6]. This molecule is increasingly studied as both a therapeutic target and a prognostic biomarker, though its functions suggest caution for safety given the complexity of lncRNA networks[4][6].
Acts as a competing endogenous RNA to "sponge" specific microRNAs (e.g., miR-145, miR-324-5p), leading to upregulation of target oncogenes (e.g., SERPINE1, SP1)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Long intergenic non-protein coding RNA 491 (LINC00491).